Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Nature Reviews Clinical Oncology – The benefit of combining antiangiogenic agents with immune-checkpoint inhibitors has been demonstrated in pivotal phase III trials across different cancer types,…